Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa

K. Hicks, D. Peng, J. L. Gajewski

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1-21% of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 μg/kg rFVIIa were given every 3 h × 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm3. Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.

Original languageEnglish (US)
Pages (from-to)975-978
Number of pages4
JournalBone Marrow Transplantation
Volume30
Issue number12
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Bone Marrow
Hemorrhage
Transplants
Therapeutics
Lung
recombinant FVIIa
Off-Label Use
Hemophilia B
Unrelated Donors
Hemophilia A
Thromboplastin
Hemostasis
Bone Marrow Transplantation
Platelet Count
Acute Myeloid Leukemia
Thrombin
Pharmaceutical Preparations
Adrenal Cortex Hormones
Maintenance
Mortality

Keywords

  • Bone marrow transplantation
  • Pulmonary hemorrhage
  • Recombinant factor VIIa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. / Hicks, K.; Peng, D.; Gajewski, J. L.

In: Bone Marrow Transplantation, Vol. 30, No. 12, 12.2002, p. 975-978.

Research output: Contribution to journalArticle

@article{d8c678402fc946a19540fe6d9f12c153,
title = "Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa",
abstract = "Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1-21{\%} of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 μg/kg rFVIIa were given every 3 h × 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm3. Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.",
keywords = "Bone marrow transplantation, Pulmonary hemorrhage, Recombinant factor VIIa",
author = "K. Hicks and D. Peng and Gajewski, {J. L.}",
year = "2002",
month = "12",
doi = "10.1038/sj.bmt.1703731",
language = "English (US)",
volume = "30",
pages = "975--978",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa

AU - Hicks, K.

AU - Peng, D.

AU - Gajewski, J. L.

PY - 2002/12

Y1 - 2002/12

N2 - Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1-21% of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 μg/kg rFVIIa were given every 3 h × 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm3. Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.

AB - Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1-21% of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 μg/kg rFVIIa were given every 3 h × 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm3. Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.

KW - Bone marrow transplantation

KW - Pulmonary hemorrhage

KW - Recombinant factor VIIa

UR - http://www.scopus.com/inward/record.url?scp=0036957457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036957457&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703731

DO - 10.1038/sj.bmt.1703731

M3 - Article

VL - 30

SP - 975

EP - 978

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -